Work

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

Year: 2013

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-013-0035-8

Authors: Dustin A. Deming, Jacob Ninan, Howard H. Bailey, Jill M. Kolesar, Jens Eickhoff, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Dona Alberti, Rebecca Marnocha, Igor Espinoza-Delgado, John Wright, George Wilding, William R. Schelman

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), National Institutes of Health, National Cancer Institute

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center, National Institutes of Health, U.S. Public Health Service, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: G1332332826, G334000260, G4194818483, Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics, G6283097126, Institutional Clinical and Translational Science Award, Phase I Clinical Trials of Anticancer Agents, Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01), Physician Scientist Training in Cancer Medicine, Mayo Clinic Comprehensive Cancer Center Support Grant, UW Comprehensive Cancer Center Support

OpenAlex ID: W2051458573

FWCI: 1.94

Cites: 16

Cited by: 44

Related to: 10